Telomere Length Emerges as Key Biomarker for Cognitive Decline in Diverse Populations

What Does Telomere Length Reveal About Cognitive Health?

Telomere length has been identified as a promising biomarker of cognitive decline in historically underrepresented populations, according to a groundbreaking study from the University of Wisconsin. The research, examining middle-aged and older American Indian/Alaska Native (AI/AN) and Black/African American (B/AA) adults, found significant associations between telomere length and immediate memory performance, highlighting biological aging as a potentially modifiable risk factor for Alzheimer's disease and related dementias (ADRD).

How Is Inclusive Research Reshaping Alzheimer’s Studies?

The study, conducted through the Wisconsin Registry for Alzheimer's Prevention (WRAP) and the University of Wisconsin Alzheimer's Disease Research Center (ADRC), represents one of the first investigations of telomere length and cognitive function specifically designed to include AI/AN participants. Researchers analyzed data from 187 participants who self-identified as B/AA and/or AI/AN, focusing on the relationship between telomere length (TL) and performance on cognitive tests. The study employed comprehensive community engagement strategies, including dedicated outreach staff from represented communities and community advisory boards that provided ongoing feedback. This approach addresses a critical gap in ADRD research, where racially minoritized populations experience disproportionately high risk of cognitive impairment and dementia yet remain significantly underrepresented in clinical studies. "This research demonstrates that inclusive cohorts, adequately powered for within-group analyses that can replicate and expand on existing findings, are within reach for committed research teams," noted the study authors in their report. The research team obtained formal Tribal Nation approvals for recruitment on Tribal lands and incorporated community input throughout the analysis process.

Participants completed comprehensive neuropsychological assessments, including the Trail Making Test (TMT) for executive function and the Rey Auditory Verbal Learning Test (RAVLT) for episodic memory. Blood samples were collected for DNA extraction and telomere measurement using monochrome multiplex quantitative real-time polymerase chain reaction (MMQ-PCR). Statistical analyses involved multivariable linear regression models progressively adjusting for sex, educational attainment, race, and chronological age. Results revealed that longer telomeres were associated with better cognitive performance, particularly in immediate memory. Specifically, telomere length positively associated with performance on the RAVLT Sum of Learning Trials 1–5, though this relationship was partially attenuated when adjusting for chronological age. The findings suggest that while chronological age confounds the relationship between telomere length and cognitive performance, biological aging may independently influence cognitive health. The study found no significant differences in telomere length distribution across racial groups, contradicting some previous research that suggested ancestry might account for observable differentials in TL. This finding highlights the complex interplay of genetic, environmental, and social factors in biological aging processes.

The research builds upon a growing body of evidence linking biological aging markers to cognitive outcomes, though results have been mixed in predominantly non-Hispanic white populations. A recent study from the Spanish Alzheimer's and Families (ALFA) cohort found similar associations between telomere length and immediate recall, while other research has shown that relationships between telomere length and cognition may vary by sex or presence of ADRD pathology. The Wisconsin study's findings also complement previous work by the same team examining cumulative life stressors and cognitive aging, suggesting biological weathering as a contributor to premature changes in memory. "Our findings are consistent with an accumulation-of-risk model, where social determinants of health contribute to biological aging and subsequent cognitive changes," the research team noted. The study's community engagement approach addresses well-documented barriers to research participation among racially minoritized communities, including lack of access to research centers and distrust of investigators.

While promising, the researchers acknowledge limitations including small sample size, which restricted exploration of complex relationships that have been observed in larger cohorts. Post hoc power analysis indicated that approximately 400 participants would be needed for adequate statistical power to detect associations between telomere length and immediate memory performance. The cross-sectional design also limited examination of telomere length as a time-varying predictor of cognitive health, which would be crucial for developing intervention studies. Despite these limitations, the findings contribute substantially to understanding biological aging as a potential intervention target in populations at highest risk for developing ADRD. The researchers emphasize that targeting preclinical ADRD and other neuropathologies will be a major focus in coming decades, with biological aging markers like telomere length potentially serving as accessible and modifiable risk factors.

For the sample of 187 participants, the majority were female (74.9%) with an average age of 58.60 years. Educational attainment averaged 14.63 years. The racial composition included 12.8% AI/AN only, 78.6% B/AA only, and 8.6% reporting more than one racial identity. Cognitive test results showed average Trail Making Test A completion time of 32.90 seconds and Trail Making Test B of 99.00 seconds, both within normal limits. For memory assessment, participants recalled an average of 44.19 words across the RAVLT learning trials and 8.40 words during the delayed recall test.

The study's multifaceted approach to community engagement included regular community-based appreciation and education events, dedicated outreach staff from the respective communities, and community-based classes of interest such as exercise and cooking. B/AA participants were given the option to complete their study visits at either the campus-based hospital or a more convenient community-based health center. For AI/AN participants, the research leadership is actively working with community partners to develop local solutions to study participation. These engagement efforts have been instrumental in building trust and facilitating biospecimen collection from communities historically excluded from research.

What Are the Industry Implications for Future Therapeutics?

Industry Context: This study represents a significant shift in ADRD research toward inclusive biomarker development and validation in diverse populations. As pharmaceutical companies increasingly focus on preclinical interventions for Alzheimer's disease, biological aging markers offer potential surrogate endpoints that could accelerate clinical trials. The findings highlight the importance of community engagement in biomarker research, particularly for companies developing precision medicine approaches to neurodegenerative diseases. With the FDA emphasizing diversity in clinical trials and the field moving toward prevention strategies, industry stakeholders should consider how biological aging interventions might complement traditional drug development pipelines targeting amyloid and tau pathologies.

Summary

A groundbreaking study from the University of Wisconsin has identified telomere length as a promising biomarker for cognitive decline in historically underrepresented populations, specifically American Indian/Alaska Native and Black/African American adults. The research, examining 187 middle-aged and older participants, found significant associations between longer telomeres and better immediate memory performance, suggesting biological aging as a potentially modifiable risk factor for Alzheimer's disease and related dementias. The study represents one of the first investigations of telomere length and cognitive function specifically designed to include AI/AN participants, employing comprehensive community engagement strategies including dedicated outreach staff, community advisory boards, and formal Tribal Nation approvals. Participants completed neuropsychological assessments and provided blood samples for telomere measurement using quantitative PCR. Results showed that longer telomeres positively associated with performance on memory tests, though this relationship was partially influenced by chronological age. Notably, the study found no significant differences in telomere length distribution across racial groups, contradicting some previous research. The findings complement existing evidence linking biological aging markers to cognitive outcomes and suggest that social determinants of health contribute to biological aging and subsequent cognitive changes. Despite limitations including small sample size and cross-sectional design, the research contributes substantially to understanding biological aging as a potential intervention target in populations at highest risk for developing dementia. The study's community engagement approach addresses documented barriers to research participation among racially minoritized communities, including lack of access and distrust of investigators. For pharmaceutical companies increasingly focused on preclinical Alzheimer's interventions, biological aging markers offer potential surrogate endpoints that could accelerate clinical trials, emphasizing the importance of diversity in biomarker research and precision medicine approaches to neurodegenerative diseases.